NAPPA appoints Tiffany Tse as Head of Hong Kong Region
A capital-strategy and cross-border BD veteran joins NAPPA to anchor the alliance's Hong Kong presence and deepen U.S.–Asia biopharma synergy.
NAPPA has appointed Tiffany Tse as Head of the Hong Kong Region. The appointment strengthens NAPPA’s strategic judgment in cross-border capital coordination and innovation translation across the U.S., China, and broader Asia.
Background
Tiffany is Founder and Managing Director of Joint PR Consultants Limited, advising corporate executives, innovative companies, and investment institutions across China and Hong Kong on growth strategy, capital pathway design, and market positioning. She is also Co-Founder and Business Lead of Bio-Pharma Consulting LLC, where she leads cross-border biopharmaceutical transactions, NewCo structural design, and capital fundraising and strategic partnership initiatives between the U.S. and Asia.
She holds an Executive MBA from Northwestern University’s Kellogg School of Management–HKUST.
Focus areas
- Structural design of U.S.–Asia cross-border biopharmaceutical transactions
- Financing and investor communication systems for innovative pharma companies
- NewCo formation and cross-border partnership model design
- Public-market positioning and IPO pathway planning, including Hong Kong listings
What this enables
Hong Kong sits at the intersection of Asian capital markets, regulatory infrastructure, and global investor flow — a critical node for biopharma companies navigating IPOs, NewCo formations, and cross-border partnerships. Tiffany’s focus is not on driving transaction volume but on ensuring that projects with genuine scientific potential and commercial value receive appropriate capital support and a credible international development pathway.